Home » Newsletters » BioWorld Science

BioWorld Science

June 16, 2011

View Archived Issues

MEGF-0444A is safe as monotherapy or combined with bevacizumab/paclitaxel in solid tumors

Interim first-in-human data support immunological efficacy of EMD-640744 in advanced solid tumors

Takeda presents new agents for treatment of diabetes

Phase III data on lipegfilgrastim for reduction of neutropenia in breast cancer

Enrollment complete in phase II CRMD-001 trial in contrast-induced acute kidney injury

Rozrolimupab well tolerated and active in patients with primary immune thrombocytopenia

Phase I/II data on navitoclax in lymphoid malignancies updated

Veliparib/temozolomide combination is safe in metastatic unresectable CRC

Lithostathine-1-alpha as a new biomarker in rheumatoid arthritis

Novel photosensitizing agents prepared at Mallinckrodt

Merck & Co. claims new hydroxycarboxylic acid HCA2 receptor agonists

Novel acetyl-CoA carboxylase inhibitors prepared by Pfizer

Roche team synthesizes novel glycogen synthase activators

Synageva BioPharma and Trimeris enter into merger agreement

Arecor and GSK join forces to develop new vaccine formulations

Resverlogix to begin phase IIb ASSURE trial of RVX-208

Abstral launched in Canada for breakthrough cancer pain

Dosing begins in first-in-human trial of VIA-3196 for dyslipidemia

Pathfast cTnI-II (cardiac troponin I) diagnostic test cleared in U.S.

APR and Labtec regain rights to ondansetron oral dispersible film

Adaptimmune begins phase I/II trial of genetically modified T-cell therapies in metastatic melanoma

FDA clears Inform Dual ISH test to help identify candidates for breast cancer therapy Herceptin

FDA accepts for review Novartis' application to expand Menveo indication to infants and toddlers

Nulojix approved in U.S. for prevention of acute kidney transplant rejection in adults

Sprycel indication expanded in Japan to include first-line treatment of chronic myeloid leukemia

Depakene approved in Japan to suppress onset of migraine attacks

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 22, 2026.
Biohaven reports details on discovery of BHV-2100
BioWorld Science
Transient receptor potential melastatin 3 (TRPM3) is a calcium-permeable TRP channel that is highly expressed in somatosensory neurons, including nociceptors of...
Meta-analysis: Anti-amyloid Alzheimer’s drugs not ‘clinically meaningful’
BioWorld
The ongoing controversy over the effectiveness of anti-amyloid drugs is about to get more heated, after a review of clinical trials showed statistically...
New GABA(B) receptor PAMs revealed in Addex Pharma patents
BioWorld Science
Addex Pharma SA has disclosed new GABA(B) receptor positive allosteric modulators (PAMs) potentially useful for the treatment of chronic cough, urinary...
MMP inhibitors divulged in Accure Therapeutics patent
BioWorld Science
Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...